ANDA 205066, held by Impax Labs Inc. Risedronate Sodium.
As of Nov 16, 2026, ANDA 205066 (Risedronate Sodium), held by Impax Labs Inc, was first approved by FDA on Jun 29, 2018, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 29, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Risedronate Sodium35MG · tablet, delayed release;oral | Risedronate Sodium | Discontinued |
| Dec 18, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 29, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters